AstraZeneca Pharma India announced on Tuesday that it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Durvalumab solution for infusion for the treatment of muscle-invasive bladder cancer (MIBC).
The approval allows the use of Durvalumab in combination with gemcitabine and cisplatin as a neoadjuvant therapy for adult patients diagnosed with MIBC, the company said in a statement.
Commenting on the development, AstraZeneca Pharma Country President and MD, Praveen Akkinepally, said, “We remain committed to bridging access gaps and expediting the availability of advanced therapies in high-burden countries like India.”